Strychnos nuxvomica

The present study was conducted to evaluate the efficacy and safety of Delphinium denudatum (Jadwar) in patients with diabetic neuropathy. A randomised single-blind standard controlled trial was carried out on 30 diagnosed patients of diabetic neuropathy at National Institute of Unani Medicine Bangalore-India. After obtaining ethical clearance, 30 eligible patients were randomly assigned into test and control groups, comprising 15 patients in each group. Patients of test group were given Delphinium denudatum wall (Jadwar) 500mg in tablet form twice daily and the patients of control group were given Strychnos nuxvomica (Azaraqi) 500 mg in tablet form twice daily for a period of 45 days. The objective parameters-Vibration perception threshold (VPT), Toronto clinical neuropathy score (TCNS) and Visual analogue scale (VAS) were statistically analysed by applying Student’s ‘t’ test, two tailed dependent for intragroup comparison, two tailed independent for intergroup comparison and Levene’s test for the homogeneity of variance. Both test and control drugs exhibited statistically significant difference in objective parameters.VPT showed statistically significant difference (p